HempFusion Exceeds New Store Targets for the Year, Products Now Available Across 18,000 Retail Locations
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, is pleased to announce that another Top 15 US supermarket chain has launched HempFusion products in the Southeast United States. HempFusion’s OTC (Over-the-Counter)) Pain Relief Cream will be added to approximately 400 stores and HempFusion’s Ingestible and Topical CBD products will now be available in 75 targeted stores.
“This new Top 15 US grocery retailer builds upon our recent announcements of launching our ingestible and topical CBD products at a major Arizona grocery chain as well as the four SKUs our Sagely Naturals division launched inside a Top 10 publicly listed US Food, Drug & Mass (FDM) retailer,” said Jason Mitchell, N.D., HempFusion‘s Co-Founder and Chief Executive Officer. “Increasingly, retail grocery chains are investing in bringing established health and wellness brands to consumers. Since the beginning of 2021, HempFusion, and its family of brands, has grown the number of doors for our products from approximately 15,000 locations to over 18,000 locations, establishing the Company as a leading health and wellness brand across our multi-channel strategy including the FDM channel. Our recent guidance to the market stated that we would launch 2,000 more locations before the end of 2021 and we have already exceeded that target with more than 3,000 new locations to date and growing,” continued Dr. Mitchell.
HempFusion is the first brand in this Southeastern United States grocery retailer to be on-shelf in the analgesic section with an OTC Pain Relief cream featuring menthol 1.75% and broad-spectrum hemp derived CBD. The skin nourishing cream will be available in approximately 400 stores.
Twelve additional SKUs of HempFusion’s Ingestibles including USDA Certified Organic Tinctures, Gummies, Sleep and Stress Support Capsules, and a variety of Topicals including Eczema Relief Cream and Pain Relief Balm, will be merchandised on CBD fixtures at nearly 100 stores.
One of a select few CBD companies who are today fully prepared to meet or exceed expected FDA guidance, HempFusion Wellness Inc. is a leading health and wellness company whose family of premium consumer brands include HempFusion™, Sagely Naturals™, Apothecanna™, and Probulin Probiotics™, one of the fastest-growing probiotics companies in the United States according to SPINs reported data.
Utilizing the power of whole-food hemp nutrition, the HempFusion family of brands’ product portfolio comprises 112 SKUs including USDA Organic Certified Tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, probiotic supplements and skin care products, a Doctor/Practitioner line, a White Label division and more. With a strong focus on research and development, HempFusion Wellness has 43 products under development.
Available from more than 18,000 US retail locations across all 50 states, HempFusion Wellness products are also available in China, Mexico, Ireland, United Kingdom, United Arab Emirates, South Korea and Canada and may be purchased online from each brand’s website, The Probulin Store on Amazon.com, Alibaba’s Tmall.com, the world’s largest cross-border online marketplace, and a multitude of additional e-commerce sites.
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to expansion of the Company’s retail footprint and the Company’s other plans, focus and objectives.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in the annual information form of the Company dated March 31, 2021, and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.